Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KYTX · as of Sep 30, 2025
Ownership Breakdown
79
Institutional Holders
▼ 2 vs Q2
$136.33M
Total Inst. Value
▲ $64.91M vs Q2
43.79M
Shares Outstanding
freeFloat 45.28%
22.70M
13F Shares Held
▼ 511,138 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KYTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VIDA VENTURES ADVISORS, LLC biological products, (no diagnostic substances) | 4.52M | 10.47% | 10.47% | $27.14B | Nov 3, 2025 | — held |
GILEAD SCIENCES, INC. biological products, (no diagnostic substances) | 4.13M | 9.55% | 9.55% | $24.76B | Nov 13, 2025 | — held |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 3.37M | 7.79% | 7.79% | $20.21B | Nov 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 1.51M | 3.50% | 3.50% | $9.07B | Nov 14, 2025 | ▼ 318.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.32M | 3.06% | 3.06% | $7.94B | Nov 7, 2025 | ▲ 9.9K |
INSIGHT HOLDINGS GROUP, LLC biological products, (no diagnostic substances) | 989.1K | 2.29% | 2.29% | $5.93B | Nov 14, 2025 | — held |
FRANKLIN RESOURCES INC biological products, (no diagnostic substances) | 677.6K | 1.57% | 1.57% | $4.07B | Nov 13, 2025 | ▼ 17.4K |
MBB PUBLIC MARKETS I LLC biological products, (no diagnostic substances) | 614.5K | 1.42% | 1.42% | $3.69B | Nov 14, 2025 | — held |
CATALIO CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 586.9K | 1.36% | 1.36% | $3.52B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 551.6K | 1.28% | 1.28% | $3.31B | Nov 14, 2025 | ▲ 99.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
17
Increased
+767.8K shares5
New Positions
first time holders18
Decreased
−1.22M shares0
Sold Out
fully exitedNet shares change (top 50)
450.6K
+767.8K / −1.22M
Net new holders
+4
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KYTX insider trading · insider activity
Source: SEC Form 4
10
Buy transactions
1
Sell transactions
10.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
CLARK IAN T director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
CLARK IAN T director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
Cohen Fred E director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
Cohen Fred E director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
SEIDENBERG BETH C director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
SEIDENBERG BETH C director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
Shaw Christi Executive Chairperson | May 27, 2026 | Tax Withhold | 4,194 | $8.59 | $36.0K | 66.7K | Form 4 ↗ |
Aktar Mert director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
Aktar Mert director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
Martini Gregory S. Chief Financial Officer | May 18, 2026 | Award | 325,000 | $8.54 | $2.78M | 325.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Kyverna Therapeutics, Inc. (KYTX) is primarily owned by institutional investors, who hold approximately 51.8% of total shares outstanding. Company insiders own approximately 54.72%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Kyverna Therapeutics, Inc. is VIDA VENTURES ADVISORS, LLC, holding approximately 4.52 million shares — equal to 10.47% of outstanding shares — as of September 30, 2025.
A total of 79 institutional investors currently hold KYTX stock, with a combined institutional value of approximately $136,330,671 as of the most recent 13F filing period.
Frequently asked questions
KYTX ownershipKyverna Therapeutics, Inc. (KYTX) is primarily owned by institutional investors, who hold approximately 51.8% of shares. The largest shareholder is VIDA VENTURES ADVISORS, LLC with a 10.47% stake. Company insiders hold 54.72%. Data sourced from SEC Form 13F as of September 30, 2025.